肿瘤防治研究2012，Vol.39Issue(2)：201-204,4.DOI:10.3971/j.issn.1000-8578.2012.02.021
改良ProMACE-CytaBOM方案治疗复发、难治侵袭性NHL的疗效评价
Evaluation of Modified ProMACE-CytaBOM Regimen in Treating Relapsed or Refractory Patients with Aggressive NHL
俸艳英 1胡晓桦 1刘志辉 1李永强 1廖小莉1
作者信息
- 1. 530021南宁,广西医科大学附属肿瘤医院化疗一科
- 折叠
摘要
Abstract
Objective To evalute the efficacy and safety of modified ProMACE-CytaBOM regimen for relapsed or refractory patients with aggresS1ve NHL. Methods Twenty-seven patients with relapsed or refractory NHL from May 2005 to September 2010 were retrospectively analyzed. They were 19 male and 8 female patients with meadian age of 47 years( range 15 to 74) years old. All patients were treated by modified ProMACE-CytaBOM cycles were repeated every 21 days. Results The overall response rates of all patients were 51. 9%(CR 22. 2%). The median progresS1on-free survival(PFS) was 7 months and the median overall survival(OS) was 19 months. The median PFS was longer in subgroups patients with B-cell and normal LDH NHL than that in those with T-cell and elevated serum LDHNHL. The median OS was longer in subgroups patients with B-cell,IPI≤2 and normal LDH than that in those with T-cell,IPI >2 and elevated serum LDHNHL. The major S1de effects were Ⅱ - Ⅲ grades of bone marrow suppresS1on and Ⅰ - Ⅱ grades of non-myeloid toxicities. ConcluS1on Modified ProMACE-CytaBOM showed promiS1ng activity and acceptable toxicity in relapsed and refractory patients with aggresS1ve NHL. However further investigation was required.关键词
改良ProMACE-CytaBOM方案/复发/难治/侵袭性非霍奇金淋巴瘤Key words
Modified ProMACE-CytaBOM regiment/ Relapsed/ Refractory/ AggresS1ve non-Hodgkin' s lymphomas分类
医药卫生引用本文复制引用
俸艳英,胡晓桦,刘志辉,李永强,廖小莉..改良ProMACE-CytaBOM方案治疗复发、难治侵袭性NHL的疗效评价[J].肿瘤防治研究,2012,39(2):201-204,4.
